EP1499357A1 - Treatment of metabolic syndrome - Google Patents

Treatment of metabolic syndrome

Info

Publication number
EP1499357A1
EP1499357A1 EP03725104A EP03725104A EP1499357A1 EP 1499357 A1 EP1499357 A1 EP 1499357A1 EP 03725104 A EP03725104 A EP 03725104A EP 03725104 A EP03725104 A EP 03725104A EP 1499357 A1 EP1499357 A1 EP 1499357A1
Authority
EP
European Patent Office
Prior art keywords
insulin
growth hormone
treatment
patients
sensitising agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03725104A
Other languages
German (de)
English (en)
French (fr)
Inventor
Bernhard Saller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pfizer Health AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0209642A external-priority patent/GB0209642D0/en
Priority claimed from GB0218912A external-priority patent/GB0218912D0/en
Application filed by Pfizer Health AB filed Critical Pfizer Health AB
Publication of EP1499357A1 publication Critical patent/EP1499357A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP03725104A 2002-04-26 2003-04-24 Treatment of metabolic syndrome Withdrawn EP1499357A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0209642A GB0209642D0 (en) 2002-04-26 2002-04-26 Metabolic syndrome
GB0209642 2002-04-26
GB0218912 2002-08-14
GB0218912A GB0218912D0 (en) 2002-08-14 2002-08-14 Metabolic syndrome
PCT/EP2003/004357 WO2003090784A1 (en) 2002-04-26 2003-04-24 Treatment of metabolic syndrome

Publications (1)

Publication Number Publication Date
EP1499357A1 true EP1499357A1 (en) 2005-01-26

Family

ID=29272006

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03725104A Withdrawn EP1499357A1 (en) 2002-04-26 2003-04-24 Treatment of metabolic syndrome

Country Status (11)

Country Link
EP (1) EP1499357A1 (pt)
JP (1) JP2005523915A (pt)
KR (1) KR20040101545A (pt)
CN (1) CN1646167A (pt)
AU (1) AU2003227683A1 (pt)
BR (1) BR0309375A (pt)
CA (1) CA2483005A1 (pt)
IL (1) IL164670A0 (pt)
MX (1) MXPA04010544A (pt)
PL (1) PL372900A1 (pt)
WO (1) WO2003090784A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10231976B2 (en) * 2010-02-08 2019-03-19 Prairie Pharmaceuticals LLC Methods for the use of progestogen as a glucocorticoid sensitizer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03090784A1 *

Also Published As

Publication number Publication date
MXPA04010544A (es) 2005-08-16
JP2005523915A (ja) 2005-08-11
PL372900A1 (en) 2005-08-08
KR20040101545A (ko) 2004-12-02
BR0309375A (pt) 2005-03-29
AU2003227683A1 (en) 2003-11-10
CA2483005A1 (en) 2003-11-06
WO2003090784A1 (en) 2003-11-06
CN1646167A (zh) 2005-07-27
IL164670A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
EP1928499B1 (en) Use of a dpp-iv inhibitor to reduce hypoglycemic events
KR101847485B1 (ko) 초속효성 인슐린의 용도
Kokot et al. Plasma leptin concentration in kidney transplant patients during the early post-transplant period.
US6274582B1 (en) Preparation for the treatment of metabolic syndrome containing human growth hormone in combination with a cortisol synthesis inhibitor
van Thiel et al. Effects of dehydroepiandrostenedione, superimposed on growth hormone substitution, on quality of life and insulin-like growth factor I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-over trial
Attanasio et al. Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study
Herrmann et al. Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome
JP2009539803A (ja) ソマトスタチン−アナログとドーパミン−または成長ホルモン受容体アンタゴニストの組合せ剤
CN104321074B (zh) 生长抑素类似物与11β‑羟化酶抑制剂的组合
AU2010257328A1 (en) Method of treatment using GH antagonist and somatostatin agonist
WO2003090784A1 (en) Treatment of metabolic syndrome
WO2002085406A9 (en) Methods and compositions for treating conditions associated with insulin resistance
ZA200408437B (en) Treatment of metabolic syndrome
KR101262123B1 (ko) 지질 대사 이상의 예방 또는 치료용 의약 조성물
Mehltretter et al. Long-term treatment with SMS 201–995 in resistant acromegaly: Effectiveness of high doses and continuous subcutaneous infusion
Frost et al. Growth hormone/insulin-like growth factor axis in human immunodeficiency virus-associated disease
LIN et al. An open, phase III study of lanreotide (Somatuline PR®) in the treatment of acromegaly
Reaven et al. Effect of enprostil on plasma glucose, insulin and lipid metabolism in patients with non-insulin-dependent diabetes mellitus
Inokuchi et al. Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics
VINIK et al. Familial hyperinsulinemia associated with secretion of an abnormal insulin, and coexistence of insulin resistance in the propositus
Umpierrez et al. Management of type 2 diabetes: Evolving strategies for treatment
CA3122581A1 (en) Methods for imaging and treatment of somatostatin-receptor positive tumors
WO2005021023A1 (en) Therapeutical conversion
Shelbaya et al. STUDY OF THE EFFECT OF BARIATRIC SURGERY ON SERUM GLUCAGON LIKE PEPTIDE-1 CONCENTRATION AND INSULIN RESISTANCE AMONG OBESE TYPE 2 DIABETIC PATIENTS
Ertorer et al. Lanreotide autogel and insulin sensitivity markers: report of 5 acromegalic patients and literature review

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041008

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

17Q First examination report despatched

Effective date: 20060928

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090526